Get started
Author

Grace Maria Antony

Observed names: G Antony, G M Antony, G. Antony, G.M. Antony, Grace Antony
Observed institutions: GlaxoSmithKline (United Kingdom), UNSW Sydney, Indian Council of Medical Research, GlaxoSmithKline Research & Development Limited (United Kingdom), National Institute of Nutrition, University of Glasgow, Newcastle University
ORCID: 0000-0001-8855-9340
Observed ORCID: 0000-0001-8855-9340
OpenAlex ID: A5037770202
A composite index to explain variations in poverty, health, nutritional status and standard of living: Use of multivariate statistical methods
2007 · G.M. Antony, K. Visweswara Rao · Public Health · 165
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial
2023 · Thierry André, Dominique Berton, et al. · JAMA Network Open · 152
PDF
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
2023 · Ana Oaknin, Bhavana Pothuri, et al. · Clinical Cancer Research · 110
PDF
Dietary habits and effect of two different educational tools on nutrition knowledge of school going adolescent girls in Hyderabad, India
2007 · D Raghunatha Rao, T Vijayapushpam, et al. · European Journal of Clinical Nutrition · 74
A qualitative assessment of nutrition knowledge levels and dietary intake of schoolchildren in Hyderabad
2003 · T Vijayapushpam, Krishna Kumari Menon, et al. · Public Health Nutrition · 47
PDF
Time to Cure for Childhood and Young Adult Acute Lymphoblastic Leukemia Is Independent of Early Risk Factors: Long-Term Follow-Up of the UKALL2003 Trial
2022 · Anthony V. Moorman, Grace Antony, et al. · Journal of Clinical Oncology · 32
PDF
Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non–small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial
2022 · Victor Moreno, Desamparados Roda, et al. · Clinical Lung Cancer · 21
PDF
Nutrition and health education intervention for student volunteers: topic-wise assessment of impact using a non-parametric test
2009 · T Vijayapushpam, Grace Maria Antony, et al. · Public Health Nutrition · 21
PDF
Genetic characterisation of childhood B‐other‐acute lymphoblastic leukaemia in UK patients by fluorescence in situ hybridisation and Multiplex Ligation‐dependent Probe Amplification
2021 · Claire J. Schwab, Daniel Murdy, et al. · British Journal of Haematology · 20
PDF
Brief intervention to reduce risky drinking in pregnancy: study protocol for a randomized controlled trial
2012 · Graeme B Wilson, Ruth McGovern, et al. · Trials · 16
PDF
The SCottish Alcoholic Liver disease Evaluation: A Population-Level Matched Cohort Study of Hospital-Based Costs, 1991-2011
2016 · Janet Bouttell, James Lewsey, et al. · PLoS ONE · 11
PDF
Scottish Keep Well health check programme: an interrupted time series analysis
2016 · Claudia Geue, James D Lewsey, et al. · Journal of Epidemiology & Community Health · 9
PDF
Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)
2024 · Annika Auranen, Matthew A. Powell, et al. · Therapeutic Advances in Medical Oncology · 8
Antitumor activity and safety of dostarlimab therapy in patients with endometrial cancer by age subgroups: A post-hoc analysis from the GARNET trial (210)
2022 · Ana Oaknin, Lucy Gilbert, et al. · Gynecologic Oncology · 2
1113P Post hoc survival outcomes based on initial and subsequent treatment in patients (pts) with mismatch repair proficient/microsatellite stable (MMRp/MSS) primary advanced or recurrent endometrial cancer (pA/R EC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
2025 · M.A. Powell, H. Roed, et al. · Annals of Oncology · 1
Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel
2025 · Dana M. Chase, Jørn Herrstedt, et al. · International Journal of Gynecological Cancer · 1
Data from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
2023 · Ana Oaknin, Bhavana Pothuri, et al. · 1
670 Correlation of durability of response with best response or early discontinuation: a post hoc analysis of the GARNET endometrial cancer cohorts
2022 · Lucy Gilbert, Kathleen Moore, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Ten Year Outcomes of UKALL 2003: A Randomised Clinical Trial of Adjusting Treatment Intensity Based on Minimal Residual Disease
2021 · Sujith Samarasinghe, Ajay Vora, et al. · Blood · 1
Antibody Kinetics Following Extracorporeal Removal
2015 · K. Schindhelm, B. Charlton, et al. · KARGER eBooks · 1
Post-hoc survival outcomes based on initial and subsequent treatment in patients with mmrp/MSS primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
2026 · Dominik Denschlag, Matthew A. Powell, et al. · International Journal of Gynecological Cancer
Supplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
2025 · Ana Oaknin, Bhavana Pothuri, et al.
PDF
46P Time to next treatment by age subgroup in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
2025 · I. Cass, J. Herrstedt, et al. · ESMO Open
PDF
Time to subsequent therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) receiving dostarlimab plus carboplatin-paclitaxel (DOST+CP) compared with pts receiving placebo plus CP (PBO+CP) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial.
2025 · Cara Amanda Mathews, Nicoline Raashouu-Jensen, et al. · Journal of Clinical Oncology
MSR106 Impact of Censoring Rules on Q-Twist Analysis and Challenges in Oncology Research: A Simulation Study
2024 · G Antony, F Lai, et al. · Value in Health
PDF
Works count: 37
Citation count: 694
H-index: 11
I10-index: 11
Year
Topic
Type